BioArctic AB (publ)
BioArctic AB (publ) Fundamental Analysis
BioArctic AB (publ) (BRCTF) shows moderate financial fundamentals with a PE ratio of 29.60, profit margin of 51.15%, and ROE of 51.84%. The company generates $2.0B in annual revenue with weak year-over-year growth of -58.22%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 21.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BRCTF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBRCTF demonstrates superior asset utilization.
Valuation Score
ModerateBRCTF shows balanced valuation metrics.
Growth Score
WeakBRCTF faces weak or negative growth trends.
Financial Health Score
ExcellentBRCTF maintains a strong and stable balance sheet.
Profitability Score
ExcellentBRCTF achieves industry-leading margins.
Key Financial Metrics
Is BRCTF Expensive or Cheap?
P/E Ratio
BRCTF trades at 29.60 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BRCTF's PEG of 1.43 indicates fair valuation.
Price to Book
The market values BioArctic AB (publ) at 15.42 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 24.35 times EBITDA. This signals the market has high growth expectations.
How Well Does BRCTF Make Money?
Net Profit Margin
For every $100 in sales, BioArctic AB (publ) keeps $51.15 as profit after all expenses.
Operating Margin
Core operations generate 63.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $51.84 in profit for every $100 of shareholder equity.
ROA
BioArctic AB (publ) generates $39.80 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioArctic AB (publ) generates strong operating cash flow of $1.44B, reflecting robust business health.
Free Cash Flow
BioArctic AB (publ) generates strong free cash flow of $1.12B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $12.66 in free cash annually.
FCF Yield
BRCTF converts 3.68% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.60
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
15.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
15.20
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.78
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.52
vs 25 benchmark
ROA
Return on assets percentage
0.40
vs 25 benchmark
ROCE
Return on capital employed
0.61
vs 25 benchmark
How BRCTF Stacks Against Its Sector Peers
| Metric | BRCTF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.60 | 29.45 | Neutral |
| ROE | 51.84% | 779.00% | Weak |
| Net Margin | 51.15% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.04 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 4.78 | 4.65 | Strong Liquidity |
| ROA | 39.80% | -19344.00% (disorted) | Strong |
BRCTF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioArctic AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-9.16%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-299.08%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-196.17%
Industry Style: Defensive, Growth, Innovation
Declining